Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(1)
•••

Post by GJS471on Feb 07, 2023 2:02pm

357 Views

Post# 35272380

No release date yet for Q4 and Full yr 2022 results

Given the history of earnings releases, it makes me wonder if they are hoping to include some additional news about the company and are holding back the date to release the results until they can make an accouncement.
Hopeful perhaps, kind of like waiting for a marriage proposal after dating for several years.

<< Previous

Bullboard Posts

Next >>

A leap into the future of tokenized finance